Research & Literature

Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis.

Chai-Adisaksopha C, Lam W, Hillis C

Leukemia & lymphoma 2016; (57(6)):1300-10 doi:10.3109/10428194.2015.1091929.

Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors.

Sasaki K, Kantarjian HM, Jain P, et al.

Cancer 2016; (122(2)):238-48 doi:10.1002/cncr.29745.

Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1.

Gu S, Chan WW, Mohi G, et al.

Blood 2016; (127(14)):1803-13 doi:10.1182/blood-2015-06-653006.

New Methodologies in the Molecular Monitoring of CML.

Yeung CC, Egan D, Radich J

Current hematologic malignancy reports 2016; (11(2)):94-101 doi:10.1007/s11899-016-0303-8.

Innovation in hematology. Perspectives: CML 2016.

Hehlmann R

Haematologica 2016; (101(6)):657-9 doi:10.3324/haematol.2016.142877.

A rare e9a1 BCR-ABL1 fusion transcript in chronic myeloid leukemia.

Miao Y, Huang Y, Feng C, et al.

International journal of laboratory hematology 2017; (39(1)):e14-e16 doi:10.1111/ijlh.12573.

Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients.

Arun AK, Senthamizhselvi A, Mani S, et al.

International journal of laboratory hematology 2017; (39(3)):235-242 doi:10.1111/ijlh.12616.

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.

Hochhaus A, Masszi T, Giles FJ, et al.

Leukemia 2017; (31(7)):1525-1531 doi:10.1038/leu.2017.63.

Comparative Analysis of Fluorescence In Situ Hybridization and Real Time Polymerase Chain Reaction in Diagnosis of Chronic Myeloid Leukemia.

Ali J, Khan SA, Rauf S-, et al.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2017; (27(1)):26-29 doi:2516.

Determination of cDNA encoding BCR/ABL fusion gene in patients with chronic myelogenous leukemia using a novel FRET-based quantum dots-DNA nanosensor.

Shamsipur M, Nasirian V, Barati A, et al.

Analytica chimica acta 2017; (966()):62-70 doi:10.1016/j.aca.2017.02.015.

E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy.

Claudiani S, Apperley JF, Gale RP, et al.

Haematologica 2017; (102(8)):e297-e299 doi:10.3324/haematol.2017.168740.

Deregulated expression of Cdc6 as BCR/ABL-dependent survival factor in chronic myeloid leukemia cells.

Zhang JH, He YL, Zhu R, et al.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2017; (39(6)):1010428317713394 doi:10.1177/1010428317713394.

Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia.

Radich JP, Mauro MJ

Hematology/oncology clinics of North America 2017; (31(4)):577-587 doi:10.1016/j.hoc.2017.04.006.

Immunohistochemistry in Acute Myeloid Leukemia.

Cruise MW

Methods in molecular biology (Clifton, N.J.) 2017; (1633()):33-49 doi:10.1007/978-1-4939-7142-8_3.

Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.

Legros L, Nicolini FE, Etienne G, et al.

Cancer 2017; (123(22)):4403-4410 doi:10.1002/cncr.30885.

Rapid reduction in BCR-ABL1 transcript predicts deep molecular response in dasatinib-treated chronic-phase chronic myeloid leukaemia patients.

Murai K, Yamaguchi K, Ito S, et al.

European journal of haematology 2018; (100(1)):27-35 doi:10.1111/ejh.12969.

How to detect the rare BCR-ABL (e14a3) transcript: A case report and literature review.

Hu LH, Pu LF, Yang DD, et al.

Oncology letters 2017; (14(5)):5619-5623 doi:10.3892/ol.2017.6847.

Further augmentation of molecular responses with dasatinib therapy in chronic myeloid leukemia patients who gained major molecular response under imatinib.

Eskazan AE

International journal of clinical oncology 2018; (23(2)):400-401 doi:10.1007/s10147-017-1214-y.

The impact of early molecular response in children and adolescents with chronic myeloid leukemia treated with imatinib: a single-center study from China.

Shao H, Zeng Z, Cen J, et al.

Leukemia & lymphoma 2018; (59(9)):2152-2158 doi:10.1080/10428194.2017.1422860.

Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study.

Kim DW, Saussele S, Williams LA, et al.

Annals of hematology 2018; (97(8)):1357-1367 doi:10.1007/s00277-018-3295-8.

The issue of financial toxicity in the management of chronic myeloid leukemia with blast crisis.

Eskazan AE

Journal of medical economics 2018; (21(7)):709-711 doi:10.1080/13696998.2018.1467919.

NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient.

Sallman DA, Brayer J, Sagatys EM, et al.

Haematologica 2018; (103(9)):e424-e426 doi:10.3324/haematol.2017.186742.

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.

Rea D, Ame S, Berger M, et al.

Cancer 2018; (124(14)):2956-2963 doi:10.1002/cncr.31411.

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.

Saussele S, Richter J, Guilhot J, et al.

The Lancet. Oncology 2018; (19(6)):747-757 doi:10.1016/S1470-2045(18)30192-X.

Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance.

Zhang J, Wang Y, Wang J, et al.

Blood cancer journal 2018; (8(7)):61 doi:10.1038/s41408-018-0093-4.

Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy.

Rossari F, Minutolo F, Orciuolo E

Journal of hematology & oncology 2018; (11(1)):84 doi:10.1186/s13045-018-0624-2.

A double Philadelphia chromosome-positive chronic myeloid leukemia patient, co-expressing P210BCR-ABL1 and P195BCR-ABL1 isoforms.

Vinhas R, Lourenço A, Santos S, et al.

Haematologica 2018; (103(11)):e549-e552 doi:10.3324/haematol.2018.192534.

Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid Leukemia.

Inselmann S, Wang Y, Saussele S, et al.

Cancer research 2018; (78(21)):6223-6234 doi:10.1158/0008-5472.CAN-18-1477.

Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology.

Radich JP, Deininger M, Abboud CN, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2018; (16(9)):1108-1135 doi:10.6004/jnccn.2018.0071.

Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value.

Hidalgo-Lόpez JE, Kanagal-Shamanna R, Quesada AE, et al.

Cancer 2018; (124(19)):3849-3855 doi:10.1002/cncr.31663.

Chronic myeloid leukemia with complex karyotypes: Prognosis and therapeutic approaches.

Asnafi AA, Deris Zayeri Z, Shahrabi S, et al.

Journal of cellular physiology 2019; (234(5)):5798-5806 doi:10.1002/jcp.27505.

Differentiating factors in treatment-free remission trials: impact of study design on results and clinical applications.

Ritchie EK

Leukemia & lymphoma 2019; (60(5)):1116-1125 doi:10.1080/10428194.2018.1535114.

Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry.

Lübking A, Dreimane A, Sandin F, et al.

Bone marrow transplantation 2019; (54(11)):1764-1774 doi:10.1038/s41409-019-0513-5.

Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA.

Brown JT, Beldorth IJ, Laosinchai-Wolf W, et al.

The Journal of molecular diagnostics : JMD 2019; (21(4)):718-733 doi:10.1016/j.jmoldx.2019.03.002.

Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia.

Dragani M, Rege-Cambrin G, Ferrero D, et al.

Leukemia & lymphoma 2019; (60(13)):3330-3332 doi:10.1080/10428194.2019.1622103.

Yet do much less...so much less!

Lipton JH

Blood 2019; (134(1)):6-7 doi:10.1182/blood.2019001014.

The role of ponatinib in chronic myeloid leukemia in the era of treatment free remission.

Andrews C, Lipton J

Leukemia & lymphoma 2019; (60(13)):3099-3101 doi:10.1080/10428194.2019.1665667.

Towards a Personalized Treatment of Patients with Chronic Myeloid Leukemia.

Rabian F, Lengline E, Rea D

Current hematologic malignancy reports 2019; (14(6)):492-500 doi:10.1007/s11899-019-00546-4.

Are we ready to use precision medicine in chronic myeloid leukemia practice?

Kim DDH

Haematologica 2019; (104(12)):2327-2329 doi:10.3324/haematol.2019.231753.

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.

Hughes TP, Mauro MJ, Cortes JE, et al.

The New England journal of medicine 2019; (381(24)):2315-2326 doi:10.1056/NEJMoa1902328.

Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician's perspective.

Pushpam D, Bakhshi S

Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 2020; (28(1)):371-385 doi:10.1007/s40199-019-00321-z.

Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia.

Gustafson D, Fish JE, Lipton JH, Aghel N

Current hematologic malignancy reports 2020; (15(1)):20-30 doi:10.1007/s11899-020-00560-x.

Validation of the EUTOS Long-Term Survival Score in Chinese Chronic Myeloid Leukemia Patients Treated with Imatinib: A Multicenter Real-World Study.

Yang X, Bai Y, Shi M, et al.

Cancer management and research 2020; (12()):1293-1301 doi:10.2147/CMAR.S237467.

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

Hochhaus A, Baccarani M, Silver RT, et al.

Leukemia 2020; (34(4)):966-984 doi:10.1038/s41375-020-0776-2.

Halving Time of BCR-ABL1 in Chronic Myeloid Leukemia: Is It Better Than Day-90 Value-A Multicenter Study From South India.

Karpurmath SV, Seshachalam A, Selvaraj K, et al.

Clinical lymphoma, myeloma & leukemia 2020; (20(5)):e205-e211 doi:10.1016/j.clml.2019.09.606.

Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study.

Cortes JE, Jiang Q, Wang J, et al.

Leukemia 2020; (34(8)):2064-2073 doi:10.1038/s41375-020-0805-1.

Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia.

Hino M, Matsumura I, Fujisawa S, et al.

International journal of hematology 2020; (112(1)):24-32 doi:10.1007/s12185-020-02878-x.

Chronic Myeloid Leukemia: Atypical Presentation and Diagnostic Pitfall in the Workup of Isolated Thrombocytosis.

Findakly D, Arslan W

Cureus 2020; (12(6)):e8498 doi:10.7759/cureus.8498.

Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia.

Annunziata M, Bonifacio M, Breccia M, et al.

Frontiers in oncology 2020; (10()):883 doi:10.3389/fonc.2020.00883.

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia.

Pfirrmann M, Clark RE, Prejzner W, et al.

Leukemia 2020; (34(8)):2138-2149 doi:10.1038/s41375-020-0931-9.

Finding new lanes: Chimeric antigen receptor (CAR) T-cells for myeloid leukemia.

Pratap S, Zhao ZJ

Cancer reports (Hoboken, N.J.) 2020; (3(2)):e1222 doi:10.1002/cnr2.1222.

Moving on from 2013 to 2020 European LeukemiaNet recommendations for treating chronic myeloid leukemia: what has changed over the 7 years?

Yilmaz U, Eskazan AE

Expert review of hematology 2020; (13(10)):1035-1038 doi:10.1080/17474086.2020.1813564.

Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Deininger MW, Shah NP, Altman JK, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2020; (18(10)):1385-1415.

The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort.

Sato E, Iriyama N, Tokuhira M, et al.

Cancer medicine 2020; (9(23)):8931-8939 doi:10.1002/cam4.3516.

[Analysis of Clinical Characteristics in De novo Chronic Myelogenous Leukemia Patients with Extramedullary T-Lymphoblastic Blast Crisis].

Guan Y, Liu Q, Huang DP, He HS

Zhongguo shi yan xue ye xue za zhi 2020; (28(5)):1528-1533 doi:10.19746/j.cnki.issn.1009-2137.2020.05.017.

A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation.

Dragani M, Rege Cambrin G, Berchialla P, et al.

Journal of clinical medicine 2020; (9(11)) doi:10.3390/jcm9113692.

Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future.

Minciacchi VR, Kumar R, Krause DS

Cells 2021; (10(1)) doi:10.3390/cells10010117.

Extramedullary Blast Crisis of Chronic Myelogenous Leukemia With a Skin Lesion: A Case Report and Literature Review.

Qi J, Zhang F, Liu Y, et al.

The American Journal of dermatopathology 2021; (43(6)):450-453 doi:10.1097/DAD.0000000000001897.

Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network.

Schäfer V, White HE, Gerrard G, et al.

Journal of cancer research and clinical oncology 2021; (147(10)):3081-3089 doi:10.1007/s00432-021-03569-8.

Measuring prognosis in chronic myeloid leukemia: what's new?

Breccia M, Efficace F, Scalzulli E, et al.

Expert review of hematology 2021; (14(6)):577-585 doi:10.1080/17474086.2021.1938534.

BCR-ABL1 p210 screening for chronic myeloid leukemia in patients with peripheral blood cytoses.

Fenu E, O'Neill SS, Insuasti-Beltran G

International journal of laboratory hematology 2021; (43(6)):1458-1464 doi:10.1111/ijlh.13635.

Early prediction of stable MR4.5 by depth of molecular response at 6 months in patients with chronic myeloid leukemia treated with frontline imatinib.

Nee A, Lipton JH, Kim DDH

Leukemia & lymphoma 2022; (63(1)):162-169 doi:10.1080/10428194.2021.1961234.

Genomic Copy Number Variants in CML Patients With the Philadelphia Chromosome (Ph+): An Update.

Zhang H, Liu M, Wang X, et al.

Frontiers in genetics 2021; (12()):697009 doi:10.3389/fgene.2021.697009.

Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network.

Specchia G, Pregno P, Breccia M, et al.

Frontiers in oncology 2021; (11()):739171 doi:10.3389/fonc.2021.739171.

Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools.

Castagnetti F, Binotto G, Capodanno I, et al.

Targeted oncology 2021; (16(6)):823-838 doi:10.1007/s11523-021-00831-4.

Blast and accelerated phase CML: room for improvement.

How J, Venkataraman V, Hobbs GS

Hematology. American Society of Hematology. Education Program 2021; (2021(1)):122-128 doi:10.1182/hematology.2021000240.

TKI discontinuation in CML: how do we make more patients eligible? How do we increase the chances of a successful treatment-free remission?

Hochhaus A, Ernst T

Hematology. American Society of Hematology. Education Program 2021; (2021(1)):106-112 doi:10.1182/hematology.2021000238.

Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report.

Maat Z, Mushtaq K, Yassin MA

Case reports in oncology 2021; (14(3)):1441-1446 doi:10.1159/000516794.

Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia.

Roskoski R

Pharmacological research 2022; (178()):106156 doi:10.1016/j.phrs.2022.106156.

How I Manage Patients with Chronic Myeloid Leukemia (CML): Perspectives from Clinical Practice.

Guru Murthy GS

Blood and lymphatic cancer : targets and therapy 2022; (12()):1-6 doi:10.2147/BLCTT.S219160.

Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia.

Haddad FG, Issa GC, Jabbour E, Yilmaz M

Expert opinion on pharmacotherapy 2022; (23(7)):751-758 doi:10.1080/14656566.2022.2064742.

Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia.

Flynn KE, Atallah E, Lin L, et al.

Haematologica 2022; (107(11)):2641-2649 doi:10.3324/haematol.2021.280377.

Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial.

Dulucq S, Nicolini FE, Rea D, et al.

Haematologica 2022; (107(12)):2859-2869 doi:10.3324/haematol.2022.280811.

Predictive Factors for Molecular Response in Chronic Myeloid Leukemia: Reduction Ratio and Halving Time of BCR::ABL1 IS Transcript Levels

Ceran F, Akıncı S, Uçar MA, et al.

Turkish journal of haematology : official journal of Turkish Society of Haematology 2022; (39(3)):196-203 doi:10.4274/tjh.galenos.2022.2022-0024.

Highly sensitive droplet digital polymerase chain reaction for BCR::ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment-free remission.

Lu L, Kok CH, Dang P, et al.

British journal of haematology 2022; (198(3)):600-603 doi:10.1111/bjh.18277.

The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia.

Saydam G, Ali R, Demir AM, et al.

International journal of hematologic oncology 2022; (11(1)):IJH38 doi:10.2217/ijh-2021-0010.

Turkey real-life data: demographic features, treatment results and effects of comorbidities in chronic myeloid leukemia.

Saydam G, Unal A, Haznedaroglu IC, et al.

International journal of hematologic oncology 2022; (11(3)):IJH40 doi:10.2217/ijh-2021-0008.

Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TM5614 combined with a tyrosine kinase inhibitor.

Takahashi N, Kameoka Y, Onizuka M, et al.

Cancer medicine 2023; (12(4)):4250-4258 doi:10.1002/cam4.5292.

[Withdrawal syndrome after tyrosine kinase inhibitors discontinuation in patients with chronic myeloid leukemia].

Chelysheva EY, Petrova AN, Shukhov OA, et al.

Terapevticheskii arkhiv 2022; (94(7)):836-843 doi:10.26442/00403660.2022.07.201747.

Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia.

Senapati J, Jabbour E, Kantarjian H, Short NJ

Leukemia 2023; (37(1)):5-17 doi:10.1038/s41375-022-01736-5.

[Acute lymphoblastic leukemia with "masked" Philadelphia chromosome].

Naganuma K, Tabayashi T, Kawada T, et al.

[Rinsho ketsueki] The Japanese journal of clinical hematology 2022; (63(11)):1525-1529 doi:10.11406/rinketsu.63.1525.

Long-term outcomes of third-line therapy with tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: A real-life experience.

Chitanava T, Matvienko I, Shuvaev V, et al.

Frontiers in oncology 2023; (13()):1138683 doi:10.3389/fonc.2023.1138683.

An interesting case of chronic myeloid leukemia (CML) with T315I mutation raising suspicion of de novo AML, a diagnostic conundrum.

Iqbal P, Shahzad A, Shahid Z, et al.

Clinical case reports 2023; (11(5)):e5908 doi:10.1002/ccr3.5908.

Occurrence of L1M Elements in Chromosomal Rearrangements Associated to Chronic Myeloid Leukemia (CML): Insights from Patient-Specific Breakpoints Characterization.

L'Abbate A, Moretti V, Pungolino E, et al.

Genes 2023; (14(7)) doi:10.3390/genes14071351.

Identification of rare atypical BCR-ABL1 transcript: A case report.

Saha J, Gopinath V, Nair CK, Roshan D

Indian journal of pathology & microbiology 2023; (66(3)):624-626 doi:10.4103/ijpm.ijpm_715_21.

An Update on the Management of Advanced Phase Chronic Myeloid Leukemia.

Short NJ, Senapati J, Jabbour E

Current hematologic malignancy reports 2023; (18(6)):234-242 doi:10.1007/s11899-023-00709-4.

Harmonizing the craft of crafting clinically endorsed small-molecule BCR-ABL tyrosine kinase inhibitors for the treatment of hematological malignancies.

Sun L, Yang PC, Luan L, et al.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2024; (193()):106678 doi:10.1016/j.ejps.2023.106678.

Exploration of treatment-free remission in CML, based on molecular monitoring.

Zhang Z, Zhou X, Zhou X, et al.

Cancer medicine 2024; (13(1)):e6849 doi:10.1002/cam4.6849.

Effect of Tyrosine Kinase Inhibitor Therapy on Estimated Glomerular Filtration Rate in Patients with Chronic Myeloid Leukemia.

Sönmez Ö, Özgür Yurttaş N, İhtiyaroğlu İ, et al.

Clinical lymphoma, myeloma & leukemia 2024; (24(4)):232-239 doi:10.1016/j.clml.2023.12.004.

Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.

Shah NP, Bhatia R, Altman JK, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2024; (22(1)):43-69 doi:10.6004/jnccn.2024.0007.

The Contemporary Role of Hematopoietic Stem Cell Transplantation in the Management of Chronic Myeloid Leukemia: Is It the Same in All Settings?

Elmakaty I, Saglio G, Al-Khabori M, et al.

Cancers 2024; (16(4)) doi:10.3390/cancers16040754.

Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group.

Iriyama N, Iwanaga E, Kimura Y, et al.

International journal of hematology 2024; (120(1)):60-70 doi:10.1007/s12185-024-03758-4.

Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase.

Haddad FG, Sasaki K, Nasr L, et al.

Cancer 2024; (130(19)):3344-3352 doi:10.1002/cncr.35384.

Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.

Hochhaus A, Wang J, Kim DW, et al.

The New England journal of medicine 2024; (391(10)):885-898 doi:10.1056/NEJMoa2400858.

Clinical Validation of the Somatic FANCD2 Mutation (c.2022-5C>T) as a Novel Molecular Biomarker for Early Disease Progression in Chronic Myeloid Leukemia: A Case-Control Study.

Alanazi N, Siyal A, Basit S, et al.

Hematology reports 2024; (16(3)):465-478 doi:10.3390/hematolrep16030045.

FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation.

Pamuk GE, Chow ECY, Ionan AC, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2024; (30(19)):4266-4271 doi:10.1158/1078-0432.CCR-24-1086.

Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study.

Yeung DT, Shanmuganathan N, Reynolds J, et al.

Blood 2024; (144(19)):1993-2001 doi:10.1182/blood.2024024657.

Asciminib: the next-generation bullet for first-line treatment of chronic myeloid leukemia.

Yoshida C, Takaku T

Med (New York, N.Y.) 2024; (5(8)):856-858 doi:10.1016/j.medj.2024.07.001.

Blast phase of chronic myeloid leukemia presenting as early T-cell precursor acute lymphoblastic leukemia.

E S, Xu J, Wang SA, et al.

American journal of clinical pathology 2025; (163(2)):231-239 doi:10.1093/ajcp/aqae115.

Ponatinib in the treatment of patients with chronic myeloid leukemia and increased cardiovascular risk: A review of management strategies.

Sacha T, Krawczyk K

Hematology, transfusion and cell therapy 2025; (47(1)):103675 doi:10.1016/j.htct.2024.04.124.

Long-term outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia.

Guilhot F, Hehlmann R

Blood 2025; (145(9)):910-920 doi:10.1182/blood.2024026311.

Digital PCR (dPCR) is able to anticipate the achievement of stable deep molecular response in adult chronic myeloid leukemia patients: results of the DEMONSTRATE study.

Bernardi S, Cavalleri A, Mutti S, et al.

Annals of hematology 2025; (104(1)):207-217 doi:10.1007/s00277-024-06100-4.

Ponatinib vs. asciminib in post-second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison.

Garcia-Gutierrez V, Huang F, Ashaye A, et al.

Frontiers in oncology 2024; (14()):1455378 doi:10.3389/fonc.2024.1455378.

Advanced-Stage Chronic Myeloid Leukemia: Options for Difficult Treatment Situations.

Atallah E, Deininger M

Drugs 2025; (85(1)):41-50 doi:10.1007/s40265-024-02108-2.

Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent.

Cavalleri A, Xhahysa B, Mutti S, et al.

Cell biology international 2025; (49(5)):570-586 doi:10.1002/cbin.70007.

Chronic Myeloid Leukemia: A Review.

Jabbour E, Kantarjian H

JAMA 2025; (333(18)):1618-1629 doi:10.1001/jama.2025.0220.

How I individualize treatment for chronic-phase CML.

Leyte-Vidal AM, Shah NP

Blood 2025; doi:10.1182/blood.2024026508.

Which Is the Best Tyrosine Kinase Inhibitor for Newly Diagnosed Chronic Myelogenous Leukemia?

Shanmuganathan N, Osborn M, Hughes TP

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2025; (45(3)):e473082 doi:10.1200/EDBK-25-473082.

How I Evaluate and Treat Resistance and Relapse in CML.

Soverini S, Castagnetti F

Blood 2025; doi:10.1182/blood.2024026511.

Very Rare Coexistence of Inversion (16), Trisomy 8, and t(9;22) in a Chronic Myeloid Leukemia Patient Progressing to Myeloblastic Crisis.

Patel DM, Trivedi PJ, Barad KD

Journal of the Association of Genetic Technologists 2025; (51(2)):75-78.

A Rare Case of Myelofibrosis Progressing to BCR-ABL1-Positive Chronic Myeloid Leukemia With Discordant Molecular Testing.

Badyal H, Dogra V, Dogra R, Shelke A

Cureus 2025; (17(6)):e86975 doi:10.7759/cureus.86975.

Revisiting Treatment-free Remission: A Case of Late Molecular Recurrence in Chronic Myeloid Leukemia.

Sharma V, Digwal A, Bagrodia V, Sharma M

The Journal of the Association of Physicians of India 2025; (73(9S)):21-22 doi:10.59556/japi.73.1123.

Clinical outcomes of allogeneic cell transplantation for patients with chronic myeloid leukemia.

McCormick B, Findley A, Diebold K, et al.

Leukemia & lymphoma 2025; (66(14)):2717-2727 doi:10.1080/10428194.2025.2564766.

[Guideline for the diagnosis and treatment of chronic myeloid leukemia in China (2025)].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2025; (46(12)):1081-1093 doi:10.3760/cma.j.cn121090-20250923-00437.

Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design.

Jambon-Barbara C, Suissa S, Dell'Aniello S, et al.

Circulation 2026; (153(13)):967-979 doi:10.1161/CIRCULATIONAHA.125.077764.